Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants

Devyani Joshi,Sarthak Shah,Christiane Chbib,Mohammad N. Uddin

DOI: https://doi.org/10.3390/ph17020184

IF: 4.6

2024-01-31

Pharmaceuticals

Abstract:The molecule (S)-4,5-dihydroxy-2,3-pentanedione (DPD) is produced by many different species of bacteria and is involved in bacterial communication. DPD is the precursor of signal molecule autoinducer-2 (AI-2) and has high potential to be used as a vaccine adjuvant. Vaccine adjuvants are compounds that enhance the stability and immunogenicity of vaccine antigens, modulate efficacy, and increase the immune response to a particular antigen. Previously, the microparticulate form of (S)-DPD was found to have an adjuvant effect with the gonorrhea vaccine. In this study, we evaluated the immunogenicity and adjuvanticity of several synthetic analogs of the (S)-DPD molecule, including ent—DPD((R)-4,5-dihydroxy-2,3-pentanedione), n-butyl—DPD ((S)-1,2-dihydroxy-3,4-octanedione), isobutyl—DPD ((S)-1,2-dihydroxy-6-methyl-3,4-heptanedione), n-hexyl—DPD ((S)-1,2-dihydroxy-3,4-decanedione), and phenyl—DPD ((S)-3,4-dihydroxy-1-phenyl-1,2-butanedione), in microparticulate formulations. The microparticulate formulations of all analogs of (S)-DPD were found to be noncytotoxic toward dendritic cells. Among these analogs, ent—DPD, n-butyl—DPD, and isobutyl—DPD were found to be immunogenic toward antigens and showed adjuvant efficacy with microparticulate gonorrhea vaccines. It was observed that n-hexyl—DPD and phenyl—DPD did not show any adjuvant effect. This study shows that synthetic analogs of (S)-DPD molecules are capable of eliciting adjuvant effects with vaccines. A future in vivo evaluation will further confirm that these analogs are promising vaccine adjuvants.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

This paper mainly discusses the potential of (S)-4,5-dihydroxy-2,3-pentanedione (DPD) analogs as vaccine adjuvants in particle formulations. In the study, the authors synthesized a series of DPD analogs and evaluated their immunogenicity and adjuvant efficacy. The experiments found that ent-DPD, n-butyl-DPD, and isobutyl-DPD exhibited adjuvant effects when combined with the particle formulation of the gonorrhea vaccine, while n-hexyl-DPD and phenyl-DPD did not show this effect. In addition, the particle formulations of all DPD analogs were proven to be non-toxic to dendritic cells. These results suggest that certain DPD analogs may serve as effective adjuvants for novel vaccines, and further in vivo evaluation is needed to confirm their potential.